Valeo Financial Advisors LLC Invests $111,000 in Glaukos Corporation (GKOS) Stock

Valeo Financial Advisors LLC acquired a new stake in Glaukos Corporation (NYSE:GKOS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,350 shares of the medical instruments supplier’s stock, valued at approximately $111,000.

Other hedge funds have also made changes to their positions in the company. California Public Employees Retirement System boosted its position in shares of Glaukos by 10.5% during the second quarter. California Public Employees Retirement System now owns 8,400 shares of the medical instruments supplier’s stock worth $348,000 after purchasing an additional 800 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Glaukos by 1.4% during the second quarter. PNC Financial Services Group Inc. now owns 70,313 shares of the medical instruments supplier’s stock worth $2,915,000 after purchasing an additional 994 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Glaukos by 93.1% during the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Glaukos by 3.7% during the second quarter. GSA Capital Partners LLP now owns 35,080 shares of the medical instruments supplier’s stock worth $1,455,000 after purchasing an additional 1,237 shares in the last quarter. Finally, Navellier & Associates Inc boosted its position in shares of Glaukos by 4.9% during the second quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock worth $1,381,000 after purchasing an additional 1,567 shares in the last quarter. 99.23% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on the stock. BidaskClub cut shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. BMO Capital Markets reissued a “buy” rating and set a $54.00 price target on shares of Glaukos in a research report on Friday, September 1st. Zacks Investment Research cut shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Wednesday, September 20th. Stifel Nicolaus reissued a “buy” rating on shares of Glaukos in a research report on Thursday, September 14th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $60.00 price target on shares of Glaukos in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $46.57.

In related news, CFO Joseph E. Gilliam acquired 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were acquired at an average cost of $23.84 per share, with a total value of $50,064.00. Following the transaction, the chief financial officer now owns 102,100 shares of the company’s stock, valued at approximately $2,434,064. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 16.40% of the company’s stock.

Glaukos Corporation (GKOS) traded up $0.13 on Friday, reaching $25.90. 714,800 shares of the company traded hands, compared to its average volume of 646,806. The company has a market cap of $890.75, a PE ratio of 214.75 and a beta of 1.02. Glaukos Corporation has a 1-year low of $23.08 and a 1-year high of $52.49.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.06. The business had revenue of $40.41 million for the quarter, compared to analysts’ expectations of $38.69 million. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. The firm’s revenue was up 36.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.03 EPS. research analysts expect that Glaukos Corporation will post -0.03 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Valeo Financial Advisors LLC Invests $111,000 in Glaukos Corporation (GKOS) Stock” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/15/valeo-financial-advisors-llc-invests-111000-in-glaukos-corporation-gkos-stock.html.

Glaukos Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

What are top analysts saying about Glaukos? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Glaukos and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit